Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 647-653

  Yang, Huiling ^a   Robinson, Margaret ^a,b   Corsa, Amoreena C ^a   Peng, Betty ^a   Cheng, Guofeng ^a   Tian, Yang ^a   Wang, Yujin ^a   Pakdaman, Rowchanak ^a   Shen, Marian ^a   Qi, Xiaoping ^a   Mo, Hongmei ^a   Tay, Chin ^a   Krawczyk, Steve ^a   Sheng, X Christopher ^a,c   Kim, Choung U ^a   Yang, Chris ^a   Delaney IV, William E ^a  

^a GILEAD SCIENCES   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Accelas Pharmaceutical Co   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CILUPREVIR; GS 6620; GS 9669; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; NS3 PROTEASE; RIBAVIRIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VEDROPREVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BEAGLE; CELL STRAIN; CONTROLLED STUDY; CROSS RESISTANCE; CYTOPATHOGENIC EFFECT; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STABILITY; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPLICON;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUORENES; HAPLORHINI; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; PROTEASE INHIBITORS; PURINES; PYRIDAZINES; QUINOLINES; RATS; REPLICON; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84893514771     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00487-13     Document Type: Article

References (43)

1. Appel N, Schaller T, Penin F, Bartenschlager R. 2006. From structure to function: new insights into hepatitis C virus RNA replication. J. Biol. Chem. 281:9833-9836. http://dx.doi.org/10.1074/jbc.R500026200.
2. Freundt EC, Lenardo MJ. 2005. Interfering with interferons: hepatitis C virus counters innate immunity. Proc. Natl. Acad. Sci. U. S. A. 102:17539-17540. http://dx.doi.org/10.1073/pnas.0509221102.
3. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 Investigators. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716. http://dx.doi.org/10.1016/S0140- 6736(10)60934-8.
4. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-1 Investigators. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa1010494.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, Study Team ADVANCE. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
6. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360:1827-1838. http://dx.doi.org/10.1056/NEJMoa0806104.
7. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:1839-1850. http://dx.doi.org/10.1056/ NEJMoa0807650.
8. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCVRESPOND-2 Investigators. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1207-1217. http://dx.doi.org/10.1056/NEJMoa1009482.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitisCvirus infection. N. Engl. J. Med. 347:975-982. http://dx.doi.org/10.1056/NEJMoa020047.
10. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mc-Cone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Study Team IDEAL. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580-593. http://dx.doi.org/10.1056/NEJMoa0808010.
11. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. http://dx.doi.org/10.1016/S0140-6736(01)06102-5.
12. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, International Study Group PEGASYS. 2004. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355. http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00010.
13. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team. 2010. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362:1292-1303. http://dx.doi.org/10.1056/NEJMoa0908014.
14. Sheng XC, Appleby T, Butler T, Cai R, Chen X, Cho A, Clarke MO, Cottell J, Delaney WE, Doerffler E, Link J, Ji M, Pakdaman R, Pyun HJ, Wu Q, Xu J, Kim CU. 2012. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg. Med. Chem. Lett. 22:2629-2634. http://dx.doi.org/10. 1016/j.bmcl.2012.01.017.
15. Dvory-Sobol H, Wong KA, Ku KS, Bae A, Lawitz EJ, Pang PS, Harris J, Miller MD, Mo H. 2012. Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients. Antimicrob. Agents Chemother. 56:5289-5295. http://dx.doi.org/10.1128/AAC.00780-12.
16. Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, Aktoudianakis V, Lew W, Ye H, Clarke M, Doerffler E, Byun D, Wang T, Babusis D, Carey AC, German P, Sauer D, Zhong W, Rossi S, Fenaux M, McHutchison JG, Perry J, Feng J, Ray AS, Kim CU. 2013. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV-infected patients. J. Med. Chem. http://dx.doi.org/10.1021/jm400201a.
17. Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Pürstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts J, Zhong W. 2011. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55:4196-4203. http://dx.doi.org/10.1128/AAC.00307-11.
18. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014.2002.
19. Zhu Q, Guo J-T, Seeger C. 2003. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J. Virol. 77: 9204-9210. http://dx.doi.org/10.1128/JVI.77.17.9204-9210.2003.
20. Pokrovskii MV, Bush CO, Beran RK, Robinson MF, Cheng G, Tirunagari N, Fenaux M, Greenstein AE, Zhong W, Delaney WE, Paulson MS. 2011. Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics. J. Virol. 85:3978-3985. http://dx.doi.org/10.1128/JVI.01760-10.
21. Paulson MS, Yang H, Shih IH, Feng JY, Mabery EM, Robinson MF, Zhong W, Delaney WE. 2009. Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b, and 2a replicons and 2a infectious virus. Antivir. Res. 83:135-142. http://dx.doi.org/10.1016/j.antiviral.2009.04.003.
22. Robinson M, Yang H, Sun SC, Peng B, Tian Y, Pagratis N, Greenstein AE, Delaney WE. 2010. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob. Agents Chemother. 54:3099-3106. http://dx.doi.org/10.1128/AAC.00289-10.
23. Robinson M, Tian Y, Delaney WE, Greenstein AE. 2011. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc. Natl. Acad. Sci. U. S. A. 108:10290-10295. http://dx.doi.org/10.1073/pnas.1101515108.
24. Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, Miller M, Mo H. 2009. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antivir. Res. 81:166-173. http://dx.doi.org/10.1016/j.antiviral.2008.11.002.
25. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. http://dx.doi.org/10.1126/science.285.5424.110.
26. Yang H, Delaney WE. 2006. A novel fluorescence-based protease assay using the endogenous NS3/4A protease activity present in the total cell lysates of HCV replicon cells. J. Clin. Virol. 36(Suppl 2):S109-S110. http://dx.doi.org/10. 1016/S1386-6532(06)80339-2.
27. Schultz B, Yang H, Delaney WE. 2011. Biochemical evaluation of HCV NS3 protease inhibitors. Curr. Protoc. Pharmacol. Chapter 13:Unit 13B7.
28. Delaney WE, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C, Locarnini S. 2001. Cross-resistance testing of antihepadnaviral compounds using novel hepatitis B virus baculoviruses encoding drug-resistant strains of hepatitis B virus. Antimicrob. Agents Chemother. 45:1705-1713. http://dx.doi.org/10.1128/AAC.45.6.1705-1713.2001.
29. Cheng G, Chan K, Yang H, Corsa A, Pokrovskii M, Paulson M, Bahador G, Zhong W, Delaney W. 2011. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob. Agents Chemother. 55:2197-2205. http://dx.doi.org/10.1128/ AAC.01382-10.
30. Prichard MN, Aseltine KR, Shipman C, Jr. 1993. MacSynergyTM II, version 1.0. University of Michigan, Ann Arbor, MI.
31. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545. http://dx.doi.org/10.1128/AAC.37.3.540.
32. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205. http://dx.doi.org/10.1016/ 0166-3542(90)90001-N.
33. Prichard MN, Shipman C, Jr. 1996. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antiviral Ther. 1:9-20.
34. Friebe P, Lohmann V, Krieger N, Bartenschlager R. 2001. Sequences in the 5= nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 75:12047-12057. http://dx.doi.org/10.1128/JVI.75.24.12047-12057.2001.
35. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. http://dx.doi.org/10.1053/j.gastro.2007.02.037.
36. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462. http://dx.doi.org/10.1053/j.gastro.2009.11.055.
37. Fridell RA, Wang C, Sun JH, O'Boyle DR, 2nd, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. 2011. Genotypic and phenotypic analysis of variants resistant to hepatitisCvirus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54:1924-1935. http://dx.doi.org/10.1002/hep.24594.
38. Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, Huang PP, Klein LL, Mo H, Molla A. 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48:2260-2266. http://dx.doi.org/10.1128/AAC.48.6.2260-2266.2004.
39. Lawitz EJ, Hill JM, Marbury T, Demicco MP, Delaney W, Yang J, Moorehead L, Mathias A, Mo H, McHutchison JG, Rodriguez-Torres M, Gordon SC. 2012. A Phase 1, randomized, placebo-controlled, threeday, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients. Antivir. Ther. http://dx.doi.org/10.3851/IMP2415.
40. Fenaux M, Eng Leavitt SSA, Lee Y-J, Mabery EM, Tian Y, Byun D, Canales E, Clarke MO, Doerffler E, Lazerwith SE, Lew W, Liu Q, Mertzman M, Morganelli P, Xu L, Ye H, Zhang J, Matles M, Murray BP, Mwangi J, Zhang J, Hashash A, Krawczyk SH, Bidgood AM, Appleby TC, Watkins WJ. 2013. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 57:804-810. http://dx.doi.org/10.1128/AAC.02052- 12.
41. Hebner CM, Lee YJ, Han B, Chiu S, Tian Y, Pagratis N, Miller MD, Mo H. 2012. In vitro pangenotypic and combination activity of sofosbuvir in stable replicon cell lines, abstr. 1875. Abstr. 63rd Annu. Meeting Am. Assoc. Study Liver Dis. American Association for the Study of Liver Diseases, Boston, M.A.
42. Lawitz E, Hill JM, Marbury TC, Rodriguez-Torres M, DeMicco MP, Quesada J, Shaw P, Gordon SC, Shelton MJ, Coombs DH, Zong J, Bae A, Wong KA, Mo H, Mondou E, Hirsch KR, Delaney WE. 2010. Three-day, dose-ranging study of the HCV NS3 protease inhibitor GS-9451. Hepatology 52:714A.
43. Link JO, Taylor JG, Xu L, Mitchell ML, Guo H, Liu H, Kato D, Kirschberg T, Sun J, Squires N, Parrish J, Kellar T, Yang Z-Y, Yang C, Matles M, Wang Y, Wang K, Cheng G, Tian Y, Mogalian E, Mondou E, Cornpropst M, Perry J, Desai MC. 9 December 2013, posting date. The discovery of ledipasvir (GS-5885), a potent once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. http://dx.doi.org/10.1021/jm401499g.